We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

2 hedge funds and large institutions have $24K invested in ELITE PHARMACEUTICAL in 2022 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

17% less capital invested

Capital invested by funds: $29K → $24K (-$5K)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BFAG
1
Blackston Financial Advisory Group
Florida
$21K – – –
Fisher Asset Management
2
Fisher Asset Management
Washington
$3K – – –

ELI Hedge Fund Activity: Q3 2022 in Review

2 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q3 2022, worth a combined $24K — down 17% from $29K a quarter earlier.

Fund positioning in ELI was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $24K of ELITE PHARMACEUTICAL stock for Q3 2022, down 17% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q3 2022 and 0 closed out.

Based on aggregated 13F filings for Q3 2022.